Stem cells therapy developer ReNeuron has gained positive data from a recent pre-clinical study which used its ReN001 stem cell therapy for disabled stroke patients.
The newly-published data show significantly improved outcomes in the key behavioural tests in the cell-treated group. A gradual improvement in function was observed between four and 12 weeks post-implantation of the cells.
The study was conducted at the Institute of Psychiatry, King's College London.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dr. John Sinden, Chief Scientific Officer of ReNeuron, said: "We are delighted to see the results of this important and confirmatory pre-clinical efficacy study.
The degree of recovery of motor function seen in this study is striking, ReNeuron said. The results confirm the strength of ReNeuron's position in the development of cell-based treatments for eligible stroke patients disabled by ischaemic stroke, a patient population who currently have no treatments available to them, the company added.
"The data from this study also fully validate the clinical approach adopted in the ongoing PISCES clinical trial with our ReN001 stem cell therapy for disabled ischaemic stroke patients."
The share price rose 1.69% to 4.5p by 08:33.
NR
-
FTSE 100 hits record highs – why is it rising and will we see more gains?Advice UK equities have been described as unloved for a long time but as the FTSE 100 hits new highs, we explain if now is the time to buy British.
-
How to invest in copperIt may be time to invest in copper as the red metal appears poised for a big jump. Dominic Frisby looks at what should investors should buy
